Macrophages in rheumatoid arthritis

Arthritis Research

Volumn 2, Issue 3, 2000, Pages 189-202

  Kinne, Raimund W ^a   Bräuer, Rolf ^a   Stuhlmüller, Bruno ^b   Palombo Kinne, Ernesta ^a   Burmester, Gerd R ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Cytokine; Fibroblast; Macrophage; Monocyte; Nitric oxide; Peripheral blood; Reactive oxygen species; Rheumatoid arthritis; Synovial membrane; T cell

Indexed keywords

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTHROPATHY; CELL DESTRUCTION; CELL FUNCTION; CELL LINEAGE; CELL POPULATION; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; HUMAN; HUMAN CELL; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; MONONUCLEAR PHAGOCYTE; MOUSE; NONHUMAN; PHAGOCYTOSIS; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; SYNOVIUM;

ARTHRITIS, RHEUMATOID; HUMANS; MACROPHAGES; SYNOVIAL MEMBRANE;

EID: 0034469464     PISSN: 14659905     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar86     Document Type: Review

References (203)

1. Pathogenesis of joint damage in rheumatoid arthritis
2. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?
3. The role of macrophages in the pathogenesis of rheumatoid arthritis
4. A proinflammatory role for IL-18 in rheumatoid arthritis
5. Macrophages, but not dendritic cells, present collagen to T cells
6. Identification of known and novel genes in activated monocytes from patients with rheumatoid arthritis
7. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis
8. Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy
9. Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane
10. The mechanisms of action of disease-modifying antirheumatic drugs: A review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines
11. The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?
12. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
13. Selective regulation of cytokine induction by adenoviral gene transfer of IkappaBalpha into human macrophages: Lipopolysaccharide-induced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is factor-kappaB independent
14. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase
15. Current comment: Basic biology and clinical application of specific cyclooxygenase-2 inhibitors
16. Mononuclear phagocytes of normal and rheumatoid synovial membrane identified by monoclonal antibodies
17. Altered integrin expression in rheumatoid synovial lining type B cells: In vitro cytokine regulation of alpha 1 beta 1, alpha 6 beta 1, and alpha v beta 5 integrins
18. Immune functions of human synovial cells. Phenotypic and T cell regulatory properties of macrophàge-like cells that express HLA-DR
19. Regulation of sialoadhesin expression on rat macrophages. Induction by glucocorticoids and enhancement by IFN-beta, IFN-gamma, IL-4, and lipopolysaccharide
20. Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes
21. Interleukin-1 receptor antagonist: Role in biology
22. Th1/Th2 cytokine balance in arthritis
23. Review: Angiogenesis: Implications for rheumatoid arthritis
24. Expression of macrophage markers by a population of T cells obtained from synovial fluid of a subgroup of patients with juvenile rheumatoid arthritis
25. + monocyte-lineage cells from the bone marrow of rheumatoid arthritis patients
26. Detection of myeloid precursors (granulocyte/macrophage colony forming units) in the bone marrow adjacent to rheumatoid arthritis joints
27. Elevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic disease
28. Distinct alterations in lineage committed progenitor cells exist in the peripheral blood of patients with rheumatoid arthritis and primary Sjogren's syndrome
29. Detection of large macrophage colony forming cells in the peripheral blood of patients with rheumatoid arthritis
30. Elevated levels of the soluble form of bone marrow stromal cell antigen 1 in the sera of patients with severe rheumatoid arthritis
31. Soluble tumour necrosis factor receptor levels reflect coagulation abnormalities in systemic juvenile chronic arthritis
32. Tissue cytokine patterns distinguish variants of rheumatoid synovitis
33. Macrophage migration and maturation within rheumatoid nodules
34. Rheumatoid arthritis: Opposing actions of haemopoietic growth factors and slow-acting anti-rheumatic drugs
35. Autologous hemopoietic stem cell transplantation: A possible cure for rheumatoid arthritis?
36. Electron microscopic study of HLA-DR and monocyte/macrophage staining cells in the rheumatoid synovial membrane
37. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity
38. Role of cytokines in rheumatoid arthritis
39. Distribution of TNF-alpha, TNF-R55 and TNF-R75 in the rheumatoid synovial membrane: TNF receptors are localized preferentially in the lining layer; TNF-alpha is distributed mainly in the vicinity of TNF receptors in the deeper layers
40. Dendritic cells: The driving force behind autoimmunity in rheumatoid arthritis?
41. Differential expression of gelatinase B (MMP-9) and stromelysin-1 (MMP- 3) by rheumatoid synovial cells in vitro and in vivo
42. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis
43. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis
44. Changes in the phenotype of monocytes/macrophages and expression of cytokine mRNA in peripheral blood and synovial fluid of patients with rheumatoid arthritis
45. Enhanced phospholipase activity in peripheral blood monocytes from patients with rheumatoid arthritis
46. Elevated cytokine messenger RNA levels in the peripheral blood of patients with rheumatoid arthritis suggest different degrees of myeloid cell activation
47. Blood monocyte activation in rheumatoid arthritis: Increased monocyte adhesiveness, integrin expression, and cytokine release
48. Urinary neopterin reflects clinical activity in patients with rheumatoid arthritis
49. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: A potentially useful laboratory marker
50. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays
51. Enhanced bacterial phagocytosis by peripheral blood monocytes in rheumatoid arthritis
52. Blood monocytes in rheumatoid arthritis are highly adherent to cultured endothelium
53. Monocyte-mediated suppression of rheumatoid factor production in normal subjects
54. Granulocyte and monocyte apheresis suppresses symptoms of rheumatoid arthritis: A pilot study
55. Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages
56. Carboxypeptidase M as a marker of macrophage maturation
57. T cell signaling of macrophage function in inflammatory disease
58. Cytokines and direct cell contact in synovitis: Relevance to therapeutic intervention
59. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression
60. Induction of human monocyte IL-1 mRNA and secretion during anti-CD3 mitogenesis requires two distinct T cell-derived signals
61. Contact with T cells modulates monocyte IL-10 production: Role of T cell membrane TNF-alpha
62. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: Possible relevance to pathophysiology of rheumatoid arthritis
63. Contribution of IL-1, CD14, and CD13 in the increased IL-6 production induced by in vitro monocyte-synoviocyte interactions
64. Cartilage degradation by cocultures of transformed macrophage and fibroblast cell lines. A model of metalloproteinase-mediated connective tissue degradation
65. Rheumatoid arthritis synovial fibroblast and U937 macrophage/monocyte cell line interaction in cartilage degradation
66. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis
67. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis
68. Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes
69. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1beta and TNF-alpha, by human macrophages
70. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells
71. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
72. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF- kappaB
73. Interleukin-18
74. Expression of macrophage-derived chemokine (MDC) mRNA in macrophages is enhanced by interleukin-1 beta, tumor necrosis factor alpha, and lipopolysaccharide
75. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-Ipr/Ipr mice by a transcriptional inhibitor of TNF-alpha
76. Mycobacterial lipoarabinomannan: An extraordinary lipoheteroglycan with profound physiological effects
77. Arabinofuranosyl-terminated and mannosylated lipoarabinomannans from Mycobacterium tuberculosis induce different levels of interleukin-12 expression in murine macrophages
78. Differential responses of human mononuclear phagocytes to mycobacterial lipoarabinomannans: Role of CD14 and the mannose receptor
79. Antibody-dependent enhancement and persistence in macrophages of an arbovirus associated with arthritis
80. Immunopathology of chronic lentivirus-induced arthritis
81. Rheumatic aspects of acquired immunodeficiency syndrome
82. Human parvovirus B19 as a causative agent for rheumatoid arthritis
83. Do sex hormones modulate the synovial macrophages in rheumatoid arthritis?
84. Thyroxine administration prevents streptococcal cell wall-induced inflammatory responses
85. Hormonal regulation of tumor necrosis factor-alpha, interleukin-12 and interleukin-10 production by activated macrophages. A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus?
86. Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis
87. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium
88. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10
89. Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis
90. Interleukin-4 inhibits prostaglandin E2 production by freshly prepared adherent rheumatoid synovial cells via inhibition of biosynthesis and gene expression of cyclo-oxygenase II but not of cyclo-oxygenase I
91. Interleukin-4 inhibits the gene expression and biosynthesis of cytosolic phospholipase A2 in lipopolysaccharide stimulated U937 macrophage cell line and freshly prepared adherent rheumatoid synovial cells
92. Antigen-specific activation, tolerization, and reactivation of the interleukin 4 pathway in vivo
93. Functional diversity of helper T lymphocytes
94. Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis
95. Immunoregulatory role of interleukin 10 in rheumatoid
96. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis
97. Analysis of serial synovial biopsies in patients with rheumatoid arthritis: Description of a control group without clinical improvement after treatment with interleukin 10 or placebo
98. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis
99. Interleukin-11. A gp130 cytokine
100. Interleukin-1 alpha and tumor necrosis factor alpha synergistically stimulate prostaglandin E2-dependent production of interleukin-11 in rheumatoid synovial fibroblasts
101. An anti-inflammatory role for interleukin-11 in established murine collagen-induced arthritis
102. Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression
103. Hematopoietic, immunomodulatory and epithelial effects of interleukin-11
104. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13
105. The presence of interleukin-13 in rheumatoid synovium and its anti-inflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis
106. + T cells
107. + T lymphocytes in rheumatoid arthritis
108. IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis
109. The role of cytokines and their inhibitors in arthritis
110. Quantitative analysis of cytokine gene expression in rheumatoid arthritis
111. TNF-alpha dominates cytokine mRNA expression in lymphoid tissues of rats developing collagen- and oil-induced arthritis
112. Cytokine gene activation in synovial membrane, regional lymph nodes, and spleen during the course of rat adjuvant arthritis
113. Anti-inflammatory effects of systemic anti-tumour necrosis factor alpha treatment in human/murine SCID arthritis
114. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: Evidence for synergistic interactions between cytokines in vivo
115. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice
116. Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor alpha in the knee-joints of patients with rheumatoid arthritis
117. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor
118. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice
119. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling
120. Processing of tumour necrosis factor-alpha precursor by metalloproteinases
121. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids
122. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor
123. Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor
124. Systemic anti-TNFα therapy in rheumatoid arthritis (RA) down-regulates synovial TNFα synthesis
125. Long-term follow-up of patients treated with infliximab (anti-TNFα antibody) in clinical trials
126. Long-term treatment with the fully human anti-TNF-antibody D2E7 slows radiographic disease progression in rheumatoid arthritis
127. 54-week clinical and radiographic results from the ATTRACT trial: A phase III study of Infliximab (Remicade™) in patients with active RA despite methotrexate
128. Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55
129. Target effector role of vascular endothelium in the inflammatory response: Insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis
130. In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis
131. Interleukin-1 reversibly inhibits the synthesis of biglycan and decorin in intact articular cartilage in culture
132. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis
133. Cytokine-induced expression of mRNAs for chemotactic factors in human synovial cells and fibroblasts
134. Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes. Effects of anti-rheumatic drugs
135. Presence of NAP-1/IL-8 in synovial fluids indicates a possible pathogenic role in rheumatoid arthritis
136. Interleukin-8 as a macrophage-derived mediator of angiogenesis
137. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
138. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides
139. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation
140. Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice
141. In situ hybridization of IL-6 in rheumatoid arthritis
142. Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-beta 1 in rheumatoid arthritis: Possible interactions in the pathogenesis of the disease
143. Transforming growth factor-beta 1 in rheumatoid synovial membrane and cartilage/pannus junction
144. Antagonistic and agonistic effects of transforming growth factor-beta and IL-1 in rheumatoid synovium
145. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor
146. Cytokines modulate routes of collagen breakdown. Review with special emphasis on mechanisms of collagen degradation in the periodontium and the burst hypothesis of periodontal disease progression
147. Transforming growth factor-beta in synovial fluids modulates Fc gamma RII (CD16) expression on mononuclear phagocytes
148. Involvement of Fcγ receptor IIIA genotypes in susceptibility to rheumatoid arthritis
149. Role of Fc receptor γ chain in inflammation and cartilage damage during experimental antigen-induced arthritis
150. Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes
151. In vivo transfer of engineered macrophages into the glomerulus: Endogenous TGF-beta-mediated defense against macrophage-induced glomerular cell activation
152. Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ: In vitro mimicking effect by transforming growth factor beta
153. Growth factor and cytokine modulation of trabecular meshwork matrix metalloproteinase and TIMP expression
154. Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release
155. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides
156. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients
157. A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases
158. Nitric oxide is a regulator of bone remodelling
159. The multiplex function of nitric oxide in (auto)immunity
160. 2-Immunohomopiperidinium salts as selective inhibitors of inducible nitric oxide synthase (iNOS)
161. Enhanced mitochondrial radical production in patients which rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma
162. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: Characterization of the cytokine cascade and cellular composition
163. Organ-specific disease provoked by systemic autoimmunity
164. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme
165. Localization of gold in synovial membrane of rheumatoid arthritis treated with sodium aurothiomalate. Studies by electron microscope and electron probe x-ray microanalysis
166. In vitro modulation of cytokine, cytokine inhibitor, and prostaglandin E release from blood mononuclear cells and synovial fibroblasts by antirheumatic drugs
167. Thiol-containing compounds inhibit the production of monocyte/macrophage-derived angiogenic activity
168. A simple inflammation model that distinguishes between the actions of anti-inflammatory and anti-rheumatic drugs
169. Methotrexate action in rheumatoid arthritis: Stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells
170. Accelerated cutaneous nodulosis during methotrexate therapy in a patient with rheumatoid arthritis
171. Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial
172. Role of lysosomes in hepatic accumulation of chloroquine
173. Interleukin-1-mediated phospholipid breakdown and arachidonic acid release in human synovial cells
174. Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages
175. Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta, and interleukin-6: Mediation by decreased mRNA stability
176. Aspirin-like molecules that covalently inactivate cyclooxygenase-2
177. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram
178. Aspirin inhibits tumor necrosis factor alpha gene expression in murine tissue macrophages
179. Apoptotic cell death in activated monocytes following incorporation of clodronate-liposomes
180. Periarticular bone alterations in chronic antigen-induced arthritis: Free and liposome-encapsulated clodronate prevent loss of bone mass in the secondary spongiosa
181. Generation of reactive oxygen species is required for bucillamine, a novel anti-rheumatic drug, to induce apoptosis in concert with copper
182. Lessons learned from gene transfer approaches
183. Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent
184. Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65
185. Transcription factors AP-1 and NF-kappa B: Where steroids meet the gold standard of anti-rheumatic drugs
186. Tissue-specific regulation of IL-6 production by IL-4. Differential effects of IL-4 on nuclear factor-kappa B activity in monocytes and fibroblasts
187. Differential effects of interleukins 10 and 4 on the production of interleukin-6 by blood and synovium monocytes in rheumatoid arthritis
188. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms
189. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10
190. Mechanisms and functions of vitamin D
191. 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti- encephalitogenic cytokines TGF-beta 1 and IL-4
192. 1 alpha-hydroxyvitamin D3 inhibits type II collagen-induced arthritis in rats
193. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis
194. Renal stones in patients with rheumatoid arthritis
195. Interleukin-1 receptor antagonist prevents expression of the metalloproteinase-generated neoepitope VDIPEN in antigen-induced arthritis
196. Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation
197. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction
198. Stimulation of articular cartilage repair in established arthritis by local administration of transforming growth factor-beta into murine knee joints
199. Molecular lysis of synovial lining cells by in vivo herpes simplex virus-thymidine kinase gene transfer
200. Feasibility of adenovirus-mediated nonsurgical synovectomy in collagen- induced arthritis-affected rhesus monkeys
201. Expression of fas ligand improves the effect of IL-4 in collagen-induced arthritis
202. Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer
203. Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model